Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidazole SCHEMBL28263725 | 1.00 | ALDH1A1 (0.59) | ALDH1A1FKBP5HTR3AHRH4 | |
| Imidazole SCHEMBL29258039 | 0.98 | ALDH1A1 (0.56) | ALDH1A1FKBP5HTR3AHRH4 | |
| Cyclohexane SCHEMBL28811591 | 0.85 | ALDH1A1 (0.81) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL27751993 | 0.83 | ALDH1A1 (0.77) | ALDH1A1FKBP5 | |
| Cyclohexane SCHEMBL28896422 | 0.83 | ALDH1A1 (0.77) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL28827258 | 0.81 | ALDH1A1 (0.52) | ALDH1A1FKBP5HTR3AHRH4 | |
| Imidazole SCHEMBL28896386 | 0.81 | ALDH1A1 (0.52) | ALDH1A1FKBP5HTR3AHRH4 | |
| Imidazole SCHEMBL2754276 | 0.78 | ALDH1A1 (0.68) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL2635292 | 0.77 | — | — | |
| Imidazole SCHEMBL2684565 | 0.77 | ALDH1A1 (1.00) | ALDH1A1FKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434192-B2 | Process and intermediates | NOVARTIS AG (CH) | 2022-09-06 | — | — | US | disclosed |
| EP-3386955-B1 | INTERMEDIATES FOR THE PREPARATION OF SACUBITRIL AND THEIR PREPARATION | NOVARTIS AG (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-20190308927-A1 | PROCESS AND INTERMEDIATES | NOVARTIS PHARMA AG (CH) | 2019-10-10 | — | — | US | disclosed |
| US-10377697-B2 | Process and intermediates | NOVARTIS AG (CH) | 2019-08-13 | — | — | US | disclosed |
| US-20180354889-A1 | NEW PROCESS AND INTERMEDIATES | NOVARTIS AG (CH) | 2018-12-13 | — | — | US | disclosed |
| EP-3386955-A1 | NEW PROCESS AND INTERMEDIATES | Novartis AG (CH) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017098430-A1 | NEW PROCESS AND INTERMEDIATES | NOVARTIS AG (CH) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308927-A1 | PROCESS AND INTERMEDIATES | MME, ACE, DNPEP | ALDH1A1 874/4885FKBP5 2468/4885HTR3A 1298/4885 |
| US-20180354889-A1 | NEW PROCESS AND INTERMEDIATES | MME, ACE, DNPEP | ALDH1A1 1335/4885FKBP5 2688/4885HTR3A 996/4885 |
| US-10377697-B2 | Process and intermediates | MME, ACE, DNPEP | ALDH1A1 874/4885FKBP5 2468/4885HTR3A 1298/4885 |
| US-11434192-B2 | Process and intermediates | MME, ACE, DNPEP | ALDH1A1 874/4885FKBP5 2468/4885HTR3A 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.